Nikolajeva-Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia.pdf
[en] Several studies have reported an impact of adult hematopoietic stem cell donor cytomegalovirus (CMV) serostatus on allogeneic hematopoietic cell transplantation outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analyzed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year nonrelapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. Data from 1177 de novo acute leukemia pediatric and adult patients transplanted within European Group for Blood and Marrow Transplantation centers between 2000 and 2012 were analyzed. CBUs were provided by the European Cord Blood Banks. The median follow-up time for live patients was 59.9 months. The recipients of CMV-seropositive and -seronegative CBUs showed a comparable RI (33% versus 35%, respectively, P = .6) and 2-year cumulative incidence of NRM (31% versus 32%, respectively, P = .5). We conclude that CBU CMV serostatus did not influence RI and NRM in de novo acute leukemia patients after allo-UCBT and should not be included as a criteria for cord blood choice.
Disciplines :
Hematology
Author, co-author :
Nikolajeva, Olga; Anthony Nolan Research Institute
Rocha, Vanderson; Churchill Hospital, University of Oxford > Department of Haematology
Danby, Robert; Anthony Nolan Research Institute
Ruggeri, Annalisa; Eurocord, Hopital Saint Louis
Volt, Fernanda; Eurocord, Hopital Saint Louis
BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire
Gomez, Susana G; Banc de Sang, Teixits, Barcelona
Kögler, Gesine; Dusseldorf Cord Blood Bank
Larghero, Jerome; Hôpital Saint-Louis, Unité de Thérapie Cellulaire
Lecchi, Lucilla; Centre of Transfusion Medicine, Cellular Therapy and Cryobiology
Sanchez Martinez, Mar; Banc de Sang, Teixits, Barcelona
Navarrete, Cristina; NHS Cord Blood Bank, NHS Blood and Transplant
Pouthier, Fabienne; Besançon Cord Blood Bank of the Etablissement Français du Sang,
Querol, Sergio; Banc de Sang, Teixits, Barcelona
Kenzey, Chantal; Eurocord, Hopital Saint Louis
Szydlo, Richard; Imperial College London
Gluckman, Eliane; Eurocord, Hopital Saint Louis
Madrigal, Alejandro; Anthony Nolan Research Institute
Lanino, E., Sacchi, N., Peters, C., Giardino, S., Rocha, V., Dini, G., Strategies of the donor search for children with second CR ALL lacking a matched sibling donor. Bone Marrow Transplant 41 (2008), S75–S79.
Matsumura, T., Narimatsu, H., Kami, M., et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 13 (2007), 577–583.
Ljungman, P., Hakki, M., Boeckh, M., Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24 (2010), 319–337.
Schmidt-Hieber, M., Labopin, M., Beelen, D., et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122 (2013), 3359–3364.
Teira, P., Battiwalla, M., Ramanathan, M., et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127 (2016), 2427–2438.
Boeckh, M., Nichols, W.G., The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004), 2003–2008.
Broers, E., van Der Holt, R., van Esser, J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95 (2000), 2240–2245.
Salzberger, B., Bowden, R.A., Hackman, R.C., Davis, C., Boeckh, M., Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90 (1997), 2502–2508.
Green, M.L., Leisenring, W.M., Xie, H., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122 (2013), 1316–1324.
Cichocki, F., Davis, Z.B., DeFor, T.E., et al. CMV reactivation is associated with reduced relapse risk, better disease-free survival and expansion of adaptive NK Cells after reduced intensity hematopoietic cell transplantation. Blood, 124, 2014.
Cichocki, F., Cooley, S., Davis, Z., et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia 30 (2016), 456–463.
Griffiths, P., Baraniak, I., Reeves, M., The pathogenesis of human cytomegalovirus. J Pathol 235 (2015), 288–297.
Albano, M.S., Taylor, P.E., Pass, R.F., et al. Cytomegalovirus (CMV) infection after umbilical cord blood transplantation and evaluation of donor screening strategies. Blood 108 (2006), 4275–4282.
Szabolcs, P., Niedzwiecki, D., Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 9 (2007), 111–122.
Remberger, M., Persson, M., Mattsson, J., Gustafsson, B., Uhlin, M., Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. Transpl Immunol 27 (2012), 59–62.
Early, E., Reen, D.J., Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses. Clin Exp Immunol 116 (1999), 527–533.
Talvensaari, K., Clave, E., Douay, C., et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 99 (2002), 1458–1464.
Chiesa, R., Gilmour, K., Qasim, W., et al. Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 156 (2012), 656–666.
Hanley, P.J., Bollard, C.M., Brunstein, C.G., Adoptive immunotherapy with the use of regulatory T cells and virus-speci fi c T cells derived from cord blood. Cytotherapy 17 (2015), 749–755.
Gaddy, J., Broxmeyer, H.E., Cord blood CD16 / 56 0 cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 180 (1997), 132–142.
Charrier, E., Cordeiro, P., Brito, R.-M., et al. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant 48 (2013), 376–382.
Przepiorka, D., Weisdorf, D., Martin, P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
Filipovich, A.H., Weisdorf, D., Pavletic, S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005), 945–956.
Rio, B., Chevret, S., Vigouroux, S., et al. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transplant 21 (2015), 445–453.
Arcese, W., Rocha, V., Labopin, M., et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 91 (2006), 223–230.
Eapen, M., Rubinstein, P., Zhang, M.-J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369 (2007), 1947–1954.
Ruggeri, A., Labopin, M., Sanz, G., et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 29 (2015), 1891–1900.
Rocha, V., Cornish, J., Sievers, E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001), 2962–2971.
Cohen, Y.C., Scaradavou, A., Stevens, C.E., et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant 46 (2011), 70–76.
Tucunduva, L., Volt, F., Cunha, R., et al. Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. Br J Haematol 169 (2015), 103–110.
Meijer, E., Dekker, A.W., Rozenberg-Arska, M., Weersink, A.J.L., Verdonck, L.F., Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 35 (2002), 703–712.
Tucunduva, L., Ruggeri, A., Sanz, G., et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49 (2014), 887–894.
Ballen, K.K., Gluckman, E., Broxmeyer, H.E., Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122 (2013), 491–498.
Rocha, V., Gluckman, E., Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147 (2009), 262–274.
Locatelli, F., Schrappe, M., Bernardo, M.E., Rutella, S., How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120 (2012), 2807–2816.
Eapen, M., Rocha, V., Sanz, G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11 (2010), 653–660.
Locatelli, F., Rocha, V., Chastang, C., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 93 (1999), 3662–3671.
Gluckman, E., Rocha, V., Donor selection for unrelated cord blood transplants. Curr Opin Immunol 18 (2006), 565–570.
Horwitz, M.E., Frassoni, F., Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. Cytotherapy 17 (2015), 730–738.
Cutler, C., Multani, P., Robbins, D., et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122 (2013), 3074–3081.
Brunstein, C.G., McKenna, D.H., DeFor, T.E., et al. Complement fragment 3a priming of umbilical cord blood progenitors: Safety profile. Biol Blood Marrow Transplant 19 (2013), 1474–1479.
Robinson, S.N., Simmons, P.J., Yang, H., Alousi, A.M., Marcos de Lima, J., Shpall, E.J., Mesenchymal stem cells in ex vivo cord blood expansion. Best Pract Res Clin Haematol 24 (2011), 83–92.
